Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 29, 2007, regarding events occurring between June 11, 2007, and June 26, 2007. The filing addresses a compliance issue with Nasdaq listing standards related to the independence of an audit committee member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes
The material change reported is the resolution of a Nasdaq listing compliance issue:
- Initial Violation: In September 2006, the Company granted a stock option for 5,000 shares to Paul Schimmel, a member of the audit committee, for his service on the scientific advisory board. This violated Rule 10A-3 of the Exchange Act, which prohibits audit committee members from receiving compensatory fees outside their board capacity.
- Remedial Action: On June 11, 2007, the Company terminated the stock option with Dr. Schimmel's consent before any shares vested.
- Regulatory Outcome: On June 26, 2007, Nasdaq notified the Company that it had regained compliance with Marketplace Rule 4350(d)(2) due to the cancellation of the option. No changes to the audit committee composition were required.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk addressed was the potential delisting or failure to satisfy continued listing rules, which was successfully mitigated by the termination of the stock option.
Investor Verification Checklist
- Confirm that the stock option granted to Paul Schimmel was fully terminated and no shares vested.
- Verify that the audit committee currently consists of at least three independent directors as required by Nasdaq Marketplace Rule 4350(d)(2)(A).
- Ensure no other compensatory arrangements exist between the Company and current audit committee members that would violate Rule 10A-3.